Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 2-17 years of age~* Systemic juvenile idiopathic arthritis with \>= 6 months persistent activity~* Presence of active disease (\>=5 active joints, or \>=2 active joints + fever + steroids)~* Inadequate clinical response to nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids due to toxicity or lack of efficacy~Exclusion Criteria:~* Wheelchair-bound or bed-ridden~* Any other autoimmune, rheumatic disease or overlap syndrome other than systemic juvenile idiopathic arthritis~* Intravenous long-acting corticosteroids or intra-articular corticosteroids within 4 weeks of baseline, or throughout study~* Disease-modifying antirheumatic drugs (DMARDs), other than methotrexate~* Previous treatment with tocilizumab

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).